RxDoctor Payments Data

Mark Parsons, OD

Optometrist · Pittsford, NYNPI 1962840306

Payments from drug & device makers

$4,923in general payments, 2019–2025

Across 81 payments — averaging $60.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$874
  • Bausch & Lomb Americas Inc.$601
  • Sight Sciences, Inc.$538
  • Amgen$487
  • Johnson & Johnson Vision Care, Inc.$364
  • Sun Pharmaceutical Industries Inc.$352
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$50010%
  • Food & beverage$4,38489%
  • Gifts$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,923 in reported general payments places this provider in the 90th percentile of 2,743 optometrist providers in New York.

See all optometrist providers in New York

Medicare billing

Part B allowed, 2024
$34,245
Medicare patients
233
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost15$8,572
RocklatanNetarsudil Mesylat/Latanoprost23$8,267
Loteprednol Etabonate14$2,002
Latanoprost156$1,478
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat53$1,017
Prednisolone Acetate21$846
Timolol Maleate105$653
Brimonidine Tartrate31$596
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha39$391
Doxycycline Hyclate11$145
Dorzolamide Hcl11$130
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim11$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$144$8,57215 claims
Aerie Pharmaceuticals, Inc.Rocklatan$11$8,26723 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$874$2,00214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,743 optometrist providers in New York.

Other optometrist in Pittsford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →